IRIS
BIELLO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.850
NA - Nord America 584
AS - Asia 509
Continente sconosciuto - Info sul continente non disponibili 119
SA - Sud America 54
AF - Africa 9
Totale 4.125
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.772
US - Stati Uniti d'America 549
SG - Singapore 156
CN - Cina 109
BD - Bangladesh 101
VN - Vietnam 85
BR - Brasile 31
FR - Francia 29
HK - Hong Kong 22
CA - Canada 12
AR - Argentina 9
DE - Germania 9
GB - Regno Unito 8
FI - Finlandia 6
PH - Filippine 6
EC - Ecuador 5
HN - Honduras 5
JM - Giamaica 5
JP - Giappone 5
TR - Turchia 5
UA - Ucraina 5
ID - Indonesia 4
MY - Malesia 4
NL - Olanda 4
IN - India 3
MX - Messico 3
PL - Polonia 3
BE - Belgio 2
CH - Svizzera 2
CO - Colombia 2
CR - Costa Rica 2
DZ - Algeria 2
ET - Etiopia 2
GT - Guatemala 2
IE - Irlanda 2
NP - Nepal 2
PY - Paraguay 2
SE - Svezia 2
SV - El Salvador 2
UY - Uruguay 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
AT - Austria 1
BS - Bahamas 1
CL - Cile 1
IQ - Iraq 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MU - Mauritius 1
PE - Perù 1
PK - Pakistan 1
PR - Porto Rico 1
RS - Serbia 1
RU - Federazione Russa 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 4.006
Salva come PNG Salva come JPEG
Città #
Genoa 1.056
Genova 1.000
Rapallo 386
Vado Ligure 247
San Jose 106
Singapore 67
Ashburn 66
Hanoi 25
Lauterbourg 25
Ho Chi Minh City 23
Hong Kong 22
Beijing 21
New York 21
Council Bluffs 18
Los Angeles 14
Santa Clara 13
Buffalo 12
Chicago 12
Milan 10
Rome 10
St Louis 10
Frankfurt am Main 8
Phoenix 8
Houston 7
São Paulo 7
Bordighera 6
Helsinki 5
Atlanta 4
Brasília 4
Dallas 4
Kingston 4
Naples 4
Princeton 4
Tokyo 4
Toronto 4
Arlington 3
Billings 3
Biên Hòa 3
Cincinnati 3
Denver 3
Kyiv 3
Orem 3
Orlando 3
Palermo 3
Queens 3
Resistencia 3
Addis Ababa 2
Amsterdam 2
Ancona 2
Bay City 2
Brownsville 2
Brussels 2
Bình Dương 2
Cassopolis 2
Cerritos 2
Charlotte 2
City of London 2
Cleveland 2
Da Nang 2
Davao City 2
Dhaka 2
Dublin 2
Fort Lauderdale 2
Guatemala City 2
Guayaquil 2
Haiphong 2
Hefei 2
Hoover 2
Houma 2
Istanbul 2
Jacksonville 2
Johannesburg 2
Kansas City 2
Las Vegas 2
Leander 2
Lexington 2
Montreal 2
Paris 2
Petaling Jaya 2
Philadelphia 2
Quito 2
Red Oak 2
San José 2
San Salvador 2
Santiago 2
Shenzhen 2
Spring Hill 2
Stockholm 2
The Bronx 2
Thái Nguyên 2
Tianjin 2
Turin 2
Vinh 2
Warsaw 2
Woodstock 2
Zurich 2
Aci Catena 1
Alexandria 1
American Fork 1
Anna 1
Totale 3.374
Salva come PNG Salva come JPEG
Nome #
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 222
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 207
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 183
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 180
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 177
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 171
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 170
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 165
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 159
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 152
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 141
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 141
Afatinib for the treatment of non-small cell lung cancer 140
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 140
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 138
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 138
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 137
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 128
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 123
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 120
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 116
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 114
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 108
Vinflunine for the treatment of non-small cell lung cancer 105
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) 99
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 96
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 95
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer 78
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 66
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 39
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 38
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 29
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 10
Totale 4.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.707
article - articoli 16.707
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.414
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022272 0 0 10 18 14 23 6 63 36 34 15 53
2022/2023431 27 36 8 39 75 68 0 43 65 5 61 4
2023/2024278 7 24 11 36 20 66 14 25 11 26 4 34
2024/2025684 35 41 17 56 77 69 59 156 24 38 62 50
2025/20261.326 172 20 72 93 170 64 179 50 116 138 122 130
2026/2027309 164 65 80 0 0 0 0 0 0 0 0 0
Totale 4.125